

A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies

Xavier Bossuyt^{1,2}, Niels Rasmussen³, Pieter van Paassen⁴, Bernard Hellmich^{5,6}, Bo Baslund⁷, Pieter Vermeersch^{2,8}, Daniel Blockmans^{1,9}, Jan-Willem Cohen Tervaert¹⁰, Elena Csernok^{5,6,*} and Jan Damoiseaux^{11,*}

Rheumatology 2017; 10.1093/rheumatology/kex170

The Publishers would like to apologize for an error in Table 2 (Test result-specific likelihood ratios) of the above paper. The heading of the second column was originally

published as '95% CI'. This has now been corrected to 'Interval' online and in print.

¹Department of Microbiology and Immunology, KU Leuven, ²Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium, ³Department of Autoimmunology and Biomarkers, Statens Seruminstitut, Copenhagen, Denmark, ⁴Department of Internal Medicine, Section Nephrology and Immunology, Maastricht University Medical Center, Maastricht, The Netherlands, ⁵Department of Internal Medicine, Rheumatology and Immunology, University Teaching Hospital Kirchheim, ⁶Vasculitis-Center Tübingen-Kirchheim, Kirchheim, Germany, ⁷Department of Rheumatology, Rigshospitalet, Copenhagen, Denmark, ⁸Department of Cardiovascular Sciences, KU Leuven, ⁹General Internal Medicine, University Hospitals Leuven, Leuven, Belgium, ¹⁰Faculty of Health, Medicine and Life Sciences, Maastricht University and ¹¹Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, The Netherlands

*Elena Csernok and Jan Damoiseaux contributed equally to this study
Correspondence to: Xavier Bossuyt, Laboratory Medicine, University Hospitals Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
E-mail: xavier.bossuyt@uzleuven.be